Market Overview:
The global lenvatinib market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing demand for targeted therapies, and growing awareness about lenvatinib. Based on type, the global lenvatinib market is segmented into 4mg and 10mg. The 10mg segment is expected to account for a larger share of the market than the 4mg segment during the forecast period. This can be attributed to its higher efficacy in treating various types of cancer as compared to 4mg. Based on application, the global lenvatinib market is divided into hospital, pharmacy, and other segments. The hospital segment accounted for a larger share of the market than other segments in 2017 and this trend is projected to continue duringthe forecast period. This can be attributedto hospitals being early adoptersof new technologiesand their greater ability toreceive reimbursementfor novel drugsfrom insurance companies .
Product Definition:
Lenvatinib is a kinase inhibitor that was developed to treat cancer. It blocks the activity of certain enzymes that help cancer cells grow and spread. Lenvatinib is used to treat different types of thyroid cancer, including papillary, follicular, and Hurthle cell carcinomas.
4mg:
4mg is a high strength prescription drug used for the treatment of chronic myeloid leukemia. It’s mechanism of action is to stop the production of abnormal cells in the blood and tissues by inhibiting the enzyme tyrosine kinase. The rise in global base pairings has led to an increase in Lenvatinib sales, which can be attributed to its ability to treat patients with acute myeloid leukemia as well as chronic myeloid leukemia.
10mg:
10mg is a standard dose for the treatment of chronic myeloid leukemia. It is also used as an off-label anti-inflammatory drug and in case of poisoning due to acetaminophen/paracetamol. The medicine works by blocking the action of cyclooxygenase, which causes inflammation.
Application Insights:
Pharmacy was the largest application segment in 2017 and is expected to maintain its dominance over the forecast period. Rising awareness regarding diseases associated with lung cancer, coupled with increasing availability of generic drugs is anticipated to drive demand for lenvatinib over the forecast period.
The hospital segment held a significant share of market in 2017 owing to rising incidence rates of lung cancer globally. In addition, lenvatinib has been found effective against non-small cell lung cancer which has led to an increase in its usage within hospitals across the globe. The growing prevalence of Non-Small Cell Lung Cancer (NSCLC) across all age groups globally has resulted in an increased number of patients admitted for treatment at hospitals which is expected to drive demand for this drug within hospitals during future years.
Regional Analysis:
North America dominated the global lenvatinib market in 2017. The presence of key players, favorable reimbursement scenario, and high healthcare expenditure are some of the major factors responsible for its largest share. In addition, lenvatinib is a part of national formulary in U.S., which ensures easy access to patients suffering from advanced lung cancer and helps reduce cost of therapy by covering up to 80% (or even more) depending on the manufacturer and state/ province.
Asia Pacific is expected to be one of the fastest-growing regions over the forecast period owing to rising healthcare expenditure, increasing patient awareness levels about available treatment options along with rapidly improving economic conditions in emerging countries such as China & India that will lead them being lucrative markets for all type 2 drugs including lenvatinib over next few years.
Key Companies: Pfizer Inc.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the Lenvatinib market. According to a study by the World Health Organization (WHO), it is estimated that there will be around 18 million new cases of cancer and 9.6 million deaths due to cancer in 2018. This number is expected to rise to 21 million new cases and 13 million deaths by 2030. This growing prevalence of cancer is expected to drive the demand for Lenvatinib, as it is an effective treatment option for various types of cancers.
- Rising awareness about Lenvatinib: There has been a rising awareness about Lenvatinib among patients and healthcare professionals in recent years owing to its efficacy in treating various types of cancers. This has led to an increase in demand for this drug, which is likely to propel the growth of the global Lenvatinib market during forecast period 2019-2025 .
Scope Of The Report
Report Attributes
Report Details
Report Title
Lenvatinib Market Research Report
By Type
4mg, 10mg
By Application
Hospital, Pharmacy, Other
By Companies
Eisai Co., Beacon Pharmaceuticals Limited, Shilpa Medicare Ltd., Everest Medicines
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
185
Number of Tables & Figures
130
Customization Available
Yes, the report can be customized as per your need.
Global Lenvatinib Market Report Segments:
The global Lenvatinib market is segmented on the basis of:
Types
4mg, 10mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eisai Co.
- Beacon Pharmaceuticals Limited
- Shilpa Medicare Ltd.
- Everest Medicines
Highlights of The Lenvatinib Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 4mg
- 10mg
- By Application:
- Hospital
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lenvatinib Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lenvatinib is a cancer drug that blocks the growth of cancer cells by blocking the action of certain proteins.
Some of the major players in the lenvatinib market are Eisai Co., Beacon Pharmaceuticals Limited, Shilpa Medicare Ltd., Everest Medicines.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lenvatinib Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lenvatinib Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lenvatinib Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lenvatinib Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lenvatinib Market Size & Forecast, 2018-2028
4.5.1 Lenvatinib Market Size and Y-o-Y Growth
4.5.2 Lenvatinib Market Absolute $ Opportunity
Chapter 5 Global Lenvatinib Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Lenvatinib Market Size Forecast by Type
5.2.1 4mg
5.2.2 10mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Lenvatinib Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Lenvatinib Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lenvatinib Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lenvatinib Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Lenvatinib Analysis and Forecast
9.1 Introduction
9.2 North America Lenvatinib Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Lenvatinib Market Size Forecast by Type
9.6.1 4mg
9.6.2 10mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Lenvatinib Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Lenvatinib Analysis and Forecast
10.1 Introduction
10.2 Europe Lenvatinib Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Lenvatinib Market Size Forecast by Type
10.6.1 4mg
10.6.2 10mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Lenvatinib Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Lenvatinib Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Lenvatinib Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Lenvatinib Market Size Forecast by Type
11.6.1 4mg
11.6.2 10mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Lenvatinib Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Lenvatinib Analysis and Forecast
12.1 Introduction
12.2 Latin America Lenvatinib Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Lenvatinib Market Size Forecast by Type
12.6.1 4mg
12.6.2 10mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Lenvatinib Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Lenvatinib Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Lenvatinib Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Lenvatinib Market Size Forecast by Type
13.6.1 4mg
13.6.2 10mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Lenvatinib Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lenvatinib Market: Competitive Dashboard
14.2 Global Lenvatinib Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eisai Co.
14.3.2 Beacon Pharmaceuticals Limited
14.3.3 Shilpa Medicare Ltd.
14.3.4 Everest Medicines
